Experimental Data Snapshot
(2009) J Med Chem 52: 7901
A novel class of 4-pyridinoxy-2-anilinopyridine-based TGF-beta type I receptor (also known as activin-like kinase 5 or ALK5) inhibitors is reported. The binding mode of this scaffold was successfully predicted by analyzing possible docked binding modes of literature inhibitors and novel synthetic ideas. Compounds such as 19 are potent ALK5 inhibitors with good physicochemical and pharmacokinetic properties and thus represent high quality leads for further optimization.
AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report |Ligand Interaction (ZZF)
Biological assembly 1 assigned by authors and generated by PISA (software)
Macromolecule Content
Entity ID: 1 | |||||
---|---|---|---|---|---|
Molecule | Chains | Sequence Length | Organism | Details | Image |
TGF-BETA RECEPTOR TYPE-1 | 306 | Homo sapiens | Mutation(s): 0  EC: 2.7.11.30 | ![]() | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for P36897 (Homo sapiens) Explore P36897  Go to UniProtKB:  P36897 | |||||
PHAROS:  P36897 GTEx:  ENSG00000106799  | |||||
Entity Groups  | |||||
Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
UniProt Group | P36897 | ||||
Sequence AnnotationsExpand | |||||
|
Ligands 2 Unique | |||||
---|---|---|---|---|---|
ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
ZZF Query on ZZF Download Ideal Coordinates CCD File  | C [auth A] | 4-({4-[(2,6-DIMETHYLPYRIDIN-3-YL)OXY]PYRIDIN-2-YL}AMINO)BENZENESULFONAMIDE C18 H18 N4 O3 S UEOZXMAOIHDDQE-UHFFFAOYSA-N | |||
EDO Query on EDO Download Ideal Coordinates CCD File  | B [auth A] | 1,2-ETHANEDIOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N |
Length ( Å ) | Angle ( ˚ ) |
---|---|
a = 41.881 | α = 90 |
b = 77.042 | β = 90 |
c = 90.387 | γ = 90 |
Software Name | Purpose |
---|---|
REFMAC | refinement |
d*TREK | data reduction |
d*TREK | data scaling |
AMoRE | phasing |
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.